Dr Emma Jones

2022

• Milutinovic, S. et al. 2022. Three-dimensional imaging reveals immune-driven tumor-associated high endothelial venules as a key correlate of tumor rejection following depletion of regulatory T cells. Cancer Research Communications 2(12), pp. 1641-1656. (10.1158/2767-9764.CRC-21-0123)

2020

• Pires, A. et al. 2020. Immune remodelling of the extracellular matrix drives loss of cancer stem cells and tumor rejection. Cancer Immunology Research 8(12), pp. 1520 - 1531. (10.1158/2326-6066.CIR-20-0070)
• Hughes, E. et al. 2020. Primary breast tumours but not lung metastases induce protective anti-tumour immune responses after Treg-depletion. Cancer Immunology, Immunotherapy 69, pp. 2063 - 2073. (10.1007/s00262-020-02603-x)
• Lauder, S. N. et al. 2020. Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3. Journal for ImmunoTherapy of Cancer 8(2), article number: e000693. (10.1136/jitc-2020-000693)

2018

• Jones, E., Gallimore, A. and Ager, A. 2018. Defining high endothelial venules and tertiary lymphoid structures in cancer. In: Tertiary Lymphoid Structures. Methods in Molecular Biology., Vol. 1845. Methods in Molecular Biology Humana Press, pp. 99-118., (10.1007/978-1-4939-8709-2_7)

2017

• Colbeck, E. J. et al. 2017. Treg depletion licenses T cell-driven HEV neogenesis and promotes tumor destruction. Cancer Immunology Research 5(11), pp. 1005-1015. (10.1158/2326-6066.CIR-17-0131)

2015

• Colbeck, E. et al. 2015. Eliminating roles for T-bet and IL-2 but revealing superior activation and proliferation as mechanisms underpinning dominance of regulatory T cells in tumors. Oncotarget 6(28), pp. 24649-24659. (10.18632/oncotarget.5584)
• Ondondo, B. et al. 2015. A distinct chemokine axis does not account for enrichment of Foxp3+ CD4+T cells in carcinogen-induced fibrosarcomas. Immunology 145(1), pp. 94-104. (10.1111/imm.12430)
• Costa Bento, D. F. et al. 2015. High endothelial venules are rare in colorectal cancers but accumulate in extra-tumoral areas with disease progression. OncoImmunology 4(3), pp. 653-660., article number: e974374. (10.4161/2162402X.2014.974374)
• Stack, G. et al. 2015. CD200 receptor restriction of myeloid cell responses antagonizes antiviral immunity and facilitates cytomegalovirus persistence within mucosal tissue. PLoS Pathogens 11(2), article number: e1004641. (10.1371/journal.ppat.1004641)

2014

• Dolton, G. M. et al. 2014. Comparison of peptide-major histocompatibility complex tetramers and dextramers for the identification of antigen-specific T cells. Clinical and Experimental Immunology 177(1), pp. 47-63. (10.1111/cei.12339)
• Ondondo, B. et al. 2014. Progression of carcinogen-induced fibrosarcomas is associated with the accumulation of naïve CD4+ T cellsviablood vessels and lymphatics. International Journal of Cancer 134(9), pp. 2156-2167. (10.1002/ijc.28556)
• Stacey, M. A. et al. 2014. Neutrophils recruited by IL-22 in peripheral tissues function as TRAIL-dependent antiviral effectors against MCMV. Cell Host and Microbe 15(4), pp. 471-483. (10.1016/j.chom.2014.03.003)

2013

• Lauder, S. N. et al. 2013. Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. European Journal of Immunology 43(10), pp. 2613-2625. (10.1002/eji.201243018)
• Russell, R. A., Martin, N., Mitar, I., Jones, E. and Sattentau, Q. J. 2013. Multiple proviral integration events after virological synapse-mediated HIV-1 spread. Virology 443(1), pp. 143-149. (10.1016/j.virol.2013.05.005)
• Pembroke, T., Christian, A., Jones, E., Hills, R. K., Wang, E. C. Y., Gallimore, A. M. and Godkin, A. J. 2013. The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon treatment. Gut n/a (10.1136/gutjnl-2013-304472)

2012

• Hindley, J. P. et al. 2012. T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T cell depletion. Cancer Research 72(21), pp. 5473-5482. (10.1158/0008-5472.CAN-12-1912)
• Pembroke, T. et al. 2012. Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4+T-cell immunity. European Journal of Immunology 42(9), pp. 2383-2394. (10.1002/eji.201142072)
• Betts, G. J. et al. 2012. Suppression of tumour-specific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut 61(8), pp. 1163-1171. (10.1136/gutjnl-2011-300970)

2011

• Hindley, J. P. et al. 2011. Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors. Cancer Research 71(3), pp. 736-746. (10.1158/0008-5472.CAN-10-1797)

2010

• Richards, H. C., Williams, A. S., Jones, E., Hindley, J. P., Godkin, A. J., Simon, A. K. and Gallimore, A. M. 2010. Novel role of regulatory T cells in limiting early neutrophil responses in skin. Immunology 131(4), pp. 583-592. (10.1111/j.1365-2567.2010.03333.x)

2009

• Lissina, A. et al. 2009. Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. Journal of Immunological Methods 340(1), pp. 11-24. (10.1016/j.jim.2008.09.014)

2003

• Wooldridge, L. et al. 2003. Anti-CD8 antibodies can inhibit or enhance peptide-MHC class I (pMHCI) multimer binding: this is paralleled by their effects on CTL activation and occurs in the absence of an interaction between pMHCI and CD8 on the cell surface. J Immunol 171, pp. 6650-60.